These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma. Franken B; van de Donk NW; Cloos JC; Zweegman S; Lokhorst HM Ther Adv Hematol; 2016 Dec; 7(6):330-344. PubMed ID: 27904737 [TBL] [Abstract][Full Text] [Related]
3. Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma. Hoy SM Target Oncol; 2016 Apr; 11(2):255-62. PubMed ID: 26972294 [TBL] [Abstract][Full Text] [Related]
4. An overview of the role of carfilzomib in the treatment of multiple myeloma. Ziogas DC; Terpos E; Kastritis E; Dimopoulos MA Expert Opin Pharmacother; 2017 Dec; 18(17):1883-1897. PubMed ID: 29134824 [TBL] [Abstract][Full Text] [Related]
5. Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma. McCormack PL Drugs; 2012 Oct; 72(15):2023-32. PubMed ID: 22994535 [TBL] [Abstract][Full Text] [Related]
6. Carfilzomib for relapsed and refractory multiple myeloma. Groen K; van de Donk N; Stege C; Zweegman S; Nijhof IS Cancer Manag Res; 2019; 11():2663-2675. PubMed ID: 31037034 [TBL] [Abstract][Full Text] [Related]
7. The emerging role of carfilzomib combination therapy in the management of multiple myeloma. Moreau P Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249 [TBL] [Abstract][Full Text] [Related]
8. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma. McBride A; Klaus JO; Stockerl-Goldstein K Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410 [TBL] [Abstract][Full Text] [Related]
9. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475 [TBL] [Abstract][Full Text] [Related]
10. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma. Steele JM J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972 [TBL] [Abstract][Full Text] [Related]
11. Role of carfilzomib in the treatment of multiple myeloma. Khan RZ; Badros A Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230 [TBL] [Abstract][Full Text] [Related]
12. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma. Stewart AK Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319 [TBL] [Abstract][Full Text] [Related]
13. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768 [TBL] [Abstract][Full Text] [Related]
14. The role of carfilzomib in relapsed/refractory multiple myeloma. Yee AJ Ther Adv Hematol; 2021; 12():20406207211019612. PubMed ID: 34163580 [TBL] [Abstract][Full Text] [Related]
15. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Thompson JL Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152 [TBL] [Abstract][Full Text] [Related]
16. Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma. Bhutani D; Zonder JA Blood Lymphat Cancer; 2017; 7():53-60. PubMed ID: 31360084 [TBL] [Abstract][Full Text] [Related]
17. Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. Manasanch EE; de Larrea CF; Zingone A; Steinberg SM; Kwok M; Tageja N; Bhutani M; Kazandjian D; Roschewski M; Wu P; Carter G; Zuchlinski D; Mulquin M; Lamping L; Costello R; Burton D; Gil LA; Figg WD; Maric I; Calvo KR; Yuan C; Stetler-Stevenson M; Korde N; Landgren O Leuk Lymphoma; 2017 Mar; 58(3):639-645. PubMed ID: 27687480 [TBL] [Abstract][Full Text] [Related]
18. Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. Nooka A; Gleason C; Casbourne D; Lonial S Biologics; 2013; 7():13-32. PubMed ID: 23386784 [TBL] [Abstract][Full Text] [Related]
19. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484 [TBL] [Abstract][Full Text] [Related]